Literature DB >> 14602790

Antecedent adrenaline attenuates the responsiveness to but not the release of counterregulatory hormones during subsequent hypoglycemia.

Bastiaan E de Galan1, Saskia J Rietjens, Cees J Tack, Sieberen P van der Werf, C G J Sweep, Jacques W M Lenders, Paul Smits.   

Abstract

Hypoglycemia unawareness is thought to be the consequence of recurrent hypoglycemia, yet the underlying mechanism is still incompletely understood. The aim of the present study was to determine the role of antecedent elevated adrenaline in the pathogenesis of hypoglycemia unawareness. Sixteen healthy volunteers (eight of either sex) participated in two experiments, performed in random order and at least 3 wk apart. During the morning, three consecutive doses of 0.04, 0.06, and 0.08 microg.kg(-1).min(-1) of adrenaline or matching placebo (normal saline) were infused for the total duration of 1 h. Three hours later, a hyperinsulinemic (360 pmol.m(-2).min(-1)) two-step hypoglycemic (5.0-3.5-2.5 mmol.liter(-1)) clamp study was performed. During hypoglycemia, hypoglycemic symptoms, counterregulatory hormones, cardiovascular responses, and cognitive function were monitored. Hypoglycemia induced similar responses of autonomic and neuroglycopenic symptoms, counterregulatory hormones, and lengthening in reaction time on the choice reaction time task, irrespective of antecedent infusions. However, prior adrenaline was associated with higher exogenous glucose requirements at hypoglycemic nadir (10.1 +/- 1.3 vs. 7.3 +/- 1.3 micromol.kg(-1).min(-1), P = 0.017), an attenuated hypoglycemia-induced fall in blood pressure (mean arterial pressure, -13 +/- 2 vs. -8 +/- 2 mm Hg, P = 0.006), and preserved cognitive function as assessed by the symbol digit test during hypoglycemia, when compared with prior placebo. We conclude that elevated adrenaline attenuates the responsiveness to, but not the release of counterregulatory hormones during subsequent hypoglycemia. As such, adrenaline's role in the development of hypoglycemia unawareness is limited.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14602790     DOI: 10.1210/jc.2003-030407

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  3 in total

1.  Carvedilol prevents impairment of the counterregulatory response in recurrently hypoglycaemic diabetic rats.

Authors:  Rawad Farhat; Eliane de Santana-Van Vliet; Gong Su; Levi Neely; Thea Benally; Owen Chan
Journal:  Endocrinol Diabetes Metab       Date:  2021-02-06

2.  Heterogeneity in Epinephrine Response to Experimental Hypoglycemia in Type 1 Diabetes and Controls.

Authors:  Yuan Zhang; Gülin Öz; Amir Moheet; Anjali Kumar; Alison Alvear; Silvia Mangia; Lynn Eberly; Elizabeth R Seaquist
Journal:  J Endocr Soc       Date:  2022-03-23

3.  Plasma Epinephrine Contributes to the Development of Experimental Hypoglycemia-Associated Autonomic Failure.

Authors:  Eric Lontchi-Yimagou; Sandra Aleksic; Raphael Hulkower; Rebekah Gospin; Akankasha Goyal; Bryan Kuo; William G Mitchell; Jee Young You; Laxmi Upadhyay; Michelle Carey; Oana A Sandu; Ilan Gabriely; Harry Shamoon; Meredith Hawkins
Journal:  J Clin Endocrinol Metab       Date:  2020-11-01       Impact factor: 5.958

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.